Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
sharewise10h
Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
Shares of The Bristol-Myers Squibb Company (NYSE: BMY)are attempting to claw their way back into positive territory after the ...
Model Portfolio For Capital Appreciation, February 2025
Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.
BioPharma Dive1h
Pfizer taps former Novartis exec to lead cancer drug push
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
American Association of Individual Investors8h
3 Undervalued Pharmaceuticals Stocks for Friday, February 07
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Q4 2024 Bristol-Myers Squibb Co Earnings Call
Christopher Boerner; Chairman of the Board, Chief Executive Officer, Chief Operating Officer; Bristol-Myers Squibb Co David Elkins; Executive Vice President, Chief Financial Officer, Member of the ...